VolitionRx Limited (VNRX) Insider Trading

Last 12 months

Insiders bought $7k on the open market and sold nothing.

Net open-market

+$7k

1 buy · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

1 / 0

executives and directors

Last open-market buy

Nov 2025

Nov 17, 2025

Get an email when VNRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 17, 2025	Cameron John Reynolds President and CEO	Bought	20,000	$0.35	$7k	0.6%	Form 4
Oct 14, 2025	Cameron John Reynolds President and CEO	Bought	110,000	$0.51	$56k	3.2%	Form 4
Oct 14, 2025	Guy Archibald Innes Director	Bought	96,153	$0.51	$49k	3.2%	Form 4
Oct 14, 2025	Timothy I Still Director	Bought	48,076	$0.51	$25k	3.2%	Form 4
Sep 12, 2025	Cameron John Reynolds President and CEO	Bought	15,000	$0.66	$10k	0.4%	Form 4
Aug 5, 2025	Guy Archibald Innes Director	Bought	78,125	$0.64	$50k	2.6%	Form 4
Aug 5, 2025	Cameron John Reynolds President and CEO	Bought	78,125	$0.64	$50k	2.2%	Form 4
Jun 12, 2025	Cameron John Reynolds President and CEO	Bought	12,500	$0.59	$7k	0.4%	Form 4
Jun 3, 2025	Guy Archibald Innes Director	Bought	20,000	$0.54	$11k	0.7%	Form 4
May 19, 2025	Jacob Vincent Micallef Chief Scientific Officer	Bought	50,000	$0.43	$22k	11%	Form 4
May 19, 2025	Cameron John Reynolds President and CEO	Bought	20,000	$0.44	$9k	0.6%	Form 4
Mar 26, 2025	Cameron John Reynolds President and CEO	Bought	181,818	$0.55	$100k	5.8%	Form 4
Mar 26, 2025	Guy Archibald Innes Director	Bought	181,818	$0.55	$100k	6.6%	Form 4
Dec 9, 2024	Guy Archibald Innes Director	Bought	174,764	$0.57	$100k	7.0%	Form 4
Dec 9, 2024	Timothy I Still Director	Bought	87,382	$0.57	$50k	6.2%	Form 4
Dec 9, 2024	Jacob Vincent Micallef Chief Scientific Officer	Bought	43,691	$0.57	$25k	9.8%	Form 4
Dec 9, 2024	Cameron John Reynolds President and CEO	Bought	139,811	$0.57	$80k	4.6%	Form 4

Nov 17, 2025
Cameron John Reynolds
President and CEO · bought 20,000 at $0.35
$7k
0.6% of stake
Oct 14, 2025
Cameron John Reynolds
President and CEO · bought 110,000 at $0.51
$56k
3.2% of stake
Oct 14, 2025
Guy Archibald Innes
Director · bought 96,153 at $0.51
$49k
3.2% of stake
Oct 14, 2025
Timothy I Still
Director · bought 48,076 at $0.51
$25k
3.2% of stake
Sep 12, 2025
Cameron John Reynolds
President and CEO · bought 15,000 at $0.66
$10k
0.4% of stake
Aug 5, 2025
Guy Archibald Innes
Director · bought 78,125 at $0.64
$50k
2.6% of stake
Aug 5, 2025
Cameron John Reynolds
President and CEO · bought 78,125 at $0.64
$50k
2.2% of stake
Jun 12, 2025
Cameron John Reynolds
President and CEO · bought 12,500 at $0.59
$7k
0.4% of stake
Jun 3, 2025
Guy Archibald Innes
Director · bought 20,000 at $0.54
$11k
0.7% of stake
May 19, 2025
Jacob Vincent Micallef
Chief Scientific Officer · bought 50,000 at $0.43
$22k
11% of stake
May 19, 2025
Cameron John Reynolds
President and CEO · bought 20,000 at $0.44
$9k
0.6% of stake
Mar 26, 2025
Cameron John Reynolds
President and CEO · bought 181,818 at $0.55
$100k
5.8% of stake
Mar 26, 2025
Guy Archibald Innes
Director · bought 181,818 at $0.55
$100k
6.6% of stake
Dec 9, 2024
Guy Archibald Innes
Director · bought 174,764 at $0.57
$100k
7.0% of stake
Dec 9, 2024
Timothy I Still
Director · bought 87,382 at $0.57
$50k
6.2% of stake
Dec 9, 2024
Jacob Vincent Micallef
Chief Scientific Officer · bought 43,691 at $0.57
$25k
9.8% of stake
Dec 9, 2024
Cameron John Reynolds
President and CEO · bought 139,811 at $0.57
$80k
4.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch VNRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: In Vitro & In Vivo Diagnostic Substances

IMDXInsight Molecular Diagnostics Inc.

QCLSQ/C Technologies, Inc.

BMRABiomerica Inc.

VTGNVistaGen Therapeutics Inc.

KRROKorro Bio Inc.

NWBONorthwest Biotherapeutics Inc.

PLSHPanacea Life Sciences Holdings, Inc.

TRAWTraws Pharma Inc.

Spot a number that looks wrong? Check it in VNRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing VNRX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.